Share this Page:
Results from the phase II FRACTION-RCC clinical trial to assess the nivolumab plus ipilimumab combination in previously treated advanced renal cell carcinoma (RCC) patients were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend.
The study looked at 46 patients with previously treated RCC that was not responding to treatment with immune checkpoint inhibitor (PD-1). These patients were treated with the ipilimumab/nivolumab combination. The objective response rate was 15.2%; none of the patients had a complete response to treatment, and 7 patients had a partial response.
These data suggest that the combination of nivolumab and ipilimumab may offer durable partial responses in patients with previously treated advanced RCC, including those who had progression of their cancer when taking immune checkpoint inhibitor therapy.
